RT @AUHealthJournal: ARCS AUSTRALIA CELEBRATES 40TH YEAR WITH TRANSFORMATIVE ANNOUNCEMENTS AT NATIONAL CONFERENCE Elevating Professional St….

This is a great story showing how the VC and risk capital ecosystem has grown symbiotically with the startup ecosystem. BTW @rayn_ong I still owe you an @nandin_innovate T Shirt!.

RT @SaysSmithy: “I love you Rick and Niki,” was the email I received from @rayn_ong (signed off with a kissing emoji) after I wrote an arti….

RT @ScienceChiefAu: PM’s Prizes for Science recipients announced tonight! Keep an eye out from 7:30pm AEDT, and celebrate the #STEM #innova….

13/13: Let's celebrate the collaborative efforts, commercialization endeavours, and royalties generated by the Gardasil® vaccine. Its journey embodies the transformational power of research and underscores the importance of #techtransfermatters and #researchimpact.

12/13: As Gardasil®'s impact reverberates worldwide, it serves as a testament to the potential of research-driven innovations. This life-saving vaccine is proof that technology transfer matters and research can have a profound societal impact. #techtransfermatters #researchimpact.

11/13: The success of Gardasil® illustrates the power of tech transfer and research impact. By translating cutting-edge science into practical solutions, lives have been saved, and the global burden of cervical cancer is decreasing. #techtransfermatters #researchimpact.

10/13: Gardasil®'s efficacy is remarkable. It protects against HPV strains responsible for 70% of cervical cancer cases and 90% of genital warts cases. The continuous development of the vaccine exemplifies its commitment to saving lives. #techtransfermatters #researchimpact.

9/13: Thanks to Gardasil®, cervical cancer is on the path to becoming a rare disease by 2022 and potentially eliminated by 2035. Australia aspires to be the first country in the world to eradicate this devastating illness. #techtransfermatters #researchimpact.

8/13: Gardasil® reached 150 countries, with over 270 million doses administered worldwide. This life-saving vaccine became a beacon of hope for regions with high cervical cancer mortality rates. Its impact continues to grow. #techtransfermatters #researchimpact.

7/13: Over time, Gardasil®'s impact grew. In 2014, Gardasil®9 expanded its protection, guarding against as many as nine strains of HPV. Its availability and affordability in developing nations accelerated the fight against cervical cancer. #techtransfermatters #researchimpact.

6/13: The clinical evidence was so compelling that the study was halted on ethical grounds, allowing young women on the placebo to receive Gardasil®. In 2006, the FDA approved Gardasil®, paving the way for its worldwide launch. #techtransfermatters #researchimpact.

5/13: CSL sub-licensed the HPV technology to Merck & Co., Inc., an ideal partner for extensive clinical trials. Phase III trials involving 12,000+ women across 13 countries showed significant protection against high-grade cervical neoplasia. #techtransfermatters #researchimpact.

4/13: UniQuest, in 1991, filed the initial patents for the HPV vaccine technology, leading to a collaboration with CSL Limited for further development. The goal was clear: commercialize the vaccine to make a global impact. #techtransfermatters #researchimpact.

3/13: In 1990, Dr Jian Zhou and Professor Ian Frazer at UQ embarked on a mission to develop an HPV vaccine. Their innovative approach involved creating virus-like particles that mimic HPV, activating the body's immune response. #techtransfermatters #researchimpact.

2/13: HPV, the major cause of cervical cancer, affects four out of five people and is linked to various cancers. In low-income countries, cervical cancer is a leading cause of cancer deaths among women. Gardasil® has changed the game. #techtransfermatters #researchimpact.

🧵THREAD: From research at The University of Queensland (@UQ_News) to global impact, Gardasil® has revolutionized the fight against cervical cancer. Let's delve into the incredible journey of this life-saving vaccine. #techtransfermatters #researchimpact @UniQuestUQ @KCALtd 1/13.

We have ~60 @ANSTO staff, @nandin_innovate founders and other special guests learning about quality from @Chemcommunicato CEO of @management_mas. Hint…. It is fascinating and there is more to it than you think

RT @georgecfeast: Really excited about this panel! ⁦⁦Top notch industry-research experience #innovation #ci2023 ⁦@timpboyle⁩ ⁦@CSIRO⁩ ⁦@Sci….

RT @anthonybayss: @timpboyle Which end up being life skills.